Research Papers:
miR-194 inhibits the proliferation, invasion, migration, and enhances the chemosensitivity of non-small cell lung cancer cells by targeting forkhead box A1 protein
Metrics: PDF 1989 views | HTML 2805 views | ?
Abstract
Xuchao Zhu1,*, Dan Li1,*, Fei Yu1,*, Chengyou Jia1, Jing Xie1, Yushui Ma1, Suyun Fan1, Haidong Cai1, Qiong Luo1, Zhongwei Lv1, Lihong Fan2
1Department of Nuclear Medicine, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, PR China
2Department of Respiration, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, PR China
*These authors contributed equally to this work
Correspondence to:
Lihong Fan, e-mail: [email protected]
Zhongwei Lv, e-mail: [email protected]
Keywords: miR-194, non-small cell lung cancer, forkhead box A1 protein
Received: October 08, 2015 Accepted: January 23, 2016 Published: February 21, 2016
ABSTRACT
Recent studies have implied that miRNAs may play a crucial role in tumor progression and may be involved in the modulation of some drug resistance in cancer cells. Earlier studies have demonstrated that miR-194 was involved in tumor metastasis and drug resistance in non-small cell lung cancer (NSCLC), whereas their expression and roles on NSCLC still need further elucidation. In the current study, we found that miR-194 is decreased in NSCLC samples compared with adjacent non-cancerous lung samples, and low expression of miR-194 predicts poor patient survival. Both in vitro and in vivo experiments showed that ectopic stable expression miR-194 suppressed proliferation, migration, invasion and metastasis and induced apoptosis in NSCLC cells and that this suppression could be reversed by reintroducing forkhead box A1 (FOXA1), a functional target of miR-194. In addition, miR-194 was downregulated in in cisplatin-resisted human NSCLC cell line-A549/DDP and overexpression of miR-194 increases cisplatin sensitivity. These findings suggested that miR-194 inhibits proliferation and metastasis and reverses cisplatin-resistance of NSCLC cells and may be useful as a new potential therapeutic target for NSCLC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7545